Xin‐Jie Chu

1.6k total citations · 1 hit paper
25 papers, 1.1k citations indexed

About

Xin‐Jie Chu is a scholar working on Molecular Biology, Organic Chemistry and Cell Biology. According to data from OpenAlex, Xin‐Jie Chu has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Organic Chemistry and 8 papers in Cell Biology. Recurrent topics in Xin‐Jie Chu's work include Synthetic Organic Chemistry Methods (8 papers), Chemical Synthesis and Analysis (6 papers) and Regulation of Appetite and Obesity (6 papers). Xin‐Jie Chu is often cited by papers focused on Synthetic Organic Chemistry Methods (8 papers), Chemical Synthesis and Analysis (6 papers) and Regulation of Appetite and Obesity (6 papers). Xin‐Jie Chu collaborates with scholars based in United States, China and Canada. Xin‐Jie Chu's co-authors include Kathryn Packman, Christian Tovar, David Bartkovitz, Nan Jiang, Zhuming Zhang, Lyubomir T. Vassilev, Kelli Glenn, Brian Higgins, Qingjie Ding and Zoran Filipovic and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Xin‐Jie Chu

25 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

2013 447 citations Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Xin‐Jie Chu

Since Specialization

Citations

This map shows the geographic impact of Xin‐Jie Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin‐Jie Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin‐Jie Chu more than expected).

Fields of papers citing papers by Xin‐Jie Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin‐Jie Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin‐Jie Chu. The network helps show where Xin‐Jie Chu may publish in the future.

Co-authorship network of co-authors of Xin‐Jie Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Xin‐Jie Chu. A scholar is included among the top collaborators of Xin‐Jie Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin‐Jie Chu. Xin‐Jie Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Pan Zhang, Yihong Peng, (unknown), Shijia Chen, (unknown), (unknown), Xin‐Jie Chu, (unknown), (unknown)	12
2	Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis 2023 ·Journal of Hepatology ·Michael Xu, Shijia Chen, (unknown), Que Liu, Yongheng Liu, (unknown), Yihong Peng, (unknown), (unknown), Pan Zhang, (unknown), (unknown), Xin‐Jie Chu	1
3	Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase 2020 ·Antimicrobial Agents and Chemotherapy ·(unknown), Xi Zhang, Weinan Zheng, (unknown), (unknown), Lan Xu, Xin‐Jie Chu, Sheng Ding, (unknown)	23
4	A novel domino reaction for the preparation of substituted non-racemic β-proline derivatives 2016 ·Tetrahedron ·Eric J. Gilbert, Andrew P. J. Brunskill, Jiaqiang Cai, (unknown), Xin‐Jie Chu, Xing Dai, Jinsong Hao, Jeffrey T. Kuethe, Zhong Lai, Hong Liu, (unknown), Qi Yan, Jack D. Scott, (unknown), Quang Truong, Shawn P. Walsh, Wen‐Lian Wu, Jared N. Cumming	1
5	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy 2014 ·Bioorganic & Medicinal Chemistry ·Zhuming Zhang, Qingjie Ding, Jinjun Liu, Jing Zhang, Nan Jiang, Xin‐Jie Chu, David Bartkovitz, Kin‐Chun Luk, Cheryl A. Janson, Christian Tovar, Zoran Filipovic, Brian Higgins, Kelli Glenn, Kathryn Packman, Lyubomir T. Vassilev, Bradford Graves	42
6	Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development breakdown → 2013 ·Journal of Medicinal Chemistry ·Qingjie Ding, Zhuming Zhang, Jinjun Liu, Nan Jiang, Jing Zhang, Tina Morgan Ross, Xin‐Jie Chu, David Bartkovitz, Frank Podlaski, Cheryl A. Janson, Christian Tovar, Zoran Filipovic, Brian Higgins, Kelli Glenn, Kathryn Packman, Lyubomir T. Vassilev, Bradford Graves	447
7	Opportunities and Challenges of Developing Peptide Drugs in the Pharmaceutical Industry 2009 ·Advances in experimental medicine and biology ·Waleed Danho, Joseph Swistok, Wajiha Khan, Xin‐Jie Chu, (unknown), David C. Fry, Hongmao Sun, (unknown), (unknown), (unknown), (unknown), Philip A. Nunn	32
8	In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials 2006 ·Molecular Cancer Therapeutics ·Wanda DePinto, Xin‐Jie Chu, Xuefeng Yin, Melissa Smith, Kathryn Packman, Petra Goelzer, Allen Lovey, Yingsi Chen, (unknown), Rachid Hamid, Qing Xiang, Christian Tovar, (unknown), (unknown), (unknown), Leopoldo Luistro, Kenneth Kolinsky, (unknown), (unknown), David Heimbrook	88
9	Design, synthesis of 1,4-cyclohexyldiamine substituted diaminopyrimidines as selective inhibitors of CDK1, CDK2 and CDK4 and their in vitro and in vivo evaluation 2005 ·Cancer Research ·Qingjie Ding, Nan Jiang, Xin‐Jie Chu, Allen Lovey, Wanda DePinto, Binh Thanh Vu, (unknown), (unknown), (unknown), John Moliterni, Kathryn Packman, Melissa Smith, (unknown), Bradford Graves, Christine Lukacs, Xuefeng Yin, Yingsi Chen	1
10	Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides 2005 ·Bioorganic & Medicinal Chemistry Letters ·Xin‐Jie Chu, David Bartkovitz, Waleed Danho, Joseph Swistok, (unknown), (unknown), Karen Rowan, (unknown), Lucía Franco, Lida Qi, Li Chen, Keith A. Yagaloff	11
11	Preparation of human Melanocortin-4 receptor agonist libraries: Linear peptides X-Y-DPhe7-Arg8-Trp(or 2-Nal)9-Z-NH2 2005 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Lida Qi, Vijay Gore, Xin‐Jie Chu, David Bartkovitz, (unknown), Joseph Swistok, Waleed Danho, Li Chen, Keith A. Yagaloff	7
12	A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides 2004 ·Bioorganic & Medicinal Chemistry ·Hongmao Sun, (unknown), Xin‐Jie Chu, (unknown), Waleed Danho, Joseph Swistok, Yao Wang, (unknown), (unknown), David C. Fry	16
13	Structure–Activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: histidine substitution 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Waleed Danho, Joseph Swistok, Lida Qi, (unknown), Karen Rowan, (unknown), Lucía Franco, Xin‐Jie Chu, (unknown), Keith A. Yagaloff	22
14	Structure–activity relationship of cyclic peptide penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH2 at the human melanocortin-1 and -4 receptors: His6 substitution 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Waleed Danho, Joseph Swistok, Lida Qi, (unknown), Karen Rowan, (unknown), Lucía Franco, Xin‐Jie Chu, (unknown), Keith A. Yagaloff	9
15	Structure–Activity relationship of linear peptide Bu-His6-DPhe7-Arg8-Trp9-Gly10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution 2003 ·Bioorganic & Medicinal Chemistry Letters ·Waleed Danho, Joseph Swistok, (unknown), (unknown), Lucía Franco, Xin‐Jie Chu, (unknown), Keith A. Yagaloff	14
16	Total Synthesis of Vancomycin—Part 1: Design and Development of Methodology 1999 ·Chemistry - A European Journal ·K. C. Nicolaou, Hui Li, Christopher N. Boddy, Joshi M. Ramanjulu, Tai‐Yuen Yue, Swaminathan Natarajan, Xin‐Jie Chu, Stefan Bräse, Frank Rübsam	1
17	Total Synthesis of Vancomycin—Part 1: Design and Development of Methodology 1999 ·Chemistry - A European Journal ·K. C. Nicolaou, Hui Li, Christopher N. Boddy, Joshi M. Ramanjulu, Tai‐Yuen Yue, Swaminathan Natarajan, Xin‐Jie Chu, Stefan Bräse, Frank Rübsam	129
18	Total synthesis and structural revision of chromomoric acid D-I methyl ester 1998 ·Tetrahedron ·Zhiyu Liu, Xin‐Jie Chu	6
19	Total synthesis of chromomoric acid B and F methyl esters 1995 ·Tetrahedron ·Xin‐Jie Chu, Hong Dong, Zhiyu Liu	8
20	A reinvestigation of the reductive ring-opening of a 3-substituted exo-4,5-epoxytricyclo[5.2.1.0^2,6]dec-8-en-3α-ol to the corresponding 3,5-diol 1993 ·Journal of the Chemical Society Perkin Transactions 1 ·Zhiyu Liu, Xin‐Jie Chu	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact